Cancer

Seeking to help distinguish its immunotoxicity competencies from the phage-based biosensor business that is its namesake, Biophage Pharma Inc. recently completed a restructuring of its contract research organization (CRO) business.

PerkinElmer has expanded and deepened its screening and diagnostics offerings with the acquisition of Spectral Genomics’ assets for molecular karyotyping technology used to evaluate chromosomal abnormalities.

Former Neos Discovery has taken on a new name to more accurately reflect its area of expertise—Trana Discovery—and has also brought on board five former Glaxo executives to commercialize the company’s technology.

In a move that will expand its oncology pipeline, Biogen Idec announced the signing of a definitive merger agreement for the acquisition of Conforma Therapeutics Corp.

Bay Area protein therapeutics and discovery company FivePrime Therapeutics Inc. inks a two-year research and license deal with Boehringer Ingelheim.

In a recent issue of Science, researchers believe they have found a way to selectively target G protein-coupled receptors (GPCRs) with small-molecule compounds that interrupt protein-protein interactions.

Merck spends $480 million to acquire GlycoFi and Abmaxis to further strengthen its antibody and yeast expression technologies

At the Strategic Research Institute’s Targeting Ubiquitin for Drug Discovery & Development conference

At the recent meeting of the American Society of Clinical Oncology

Researchers at the Broad Institute

With hormone therapy, is the risk relative?

High-throughput assay specialist Carna Biosciences